Loading...
ALXP
ALBIO
Market cap17mUSD
Oct 28, Last price  
0.84EUR
1D
0.72%
1Q
-7.08%
Jan 2017
-54.10%
IPO
-93.82%
Name

Biosynex SA

Chart & performance

D1W1MN
ALXP:ALBIO chart
P/E
—
P/S
0.17
EPS
—
Vol. 1Y
86.54%
Shs. 5Y
—
Rev. 5Y
42.61%
Div Yld LY
—
Div Yld TTM
—
Revenues
95m
95,200,000
Net income
-58m
-58,200,000
CFO
-6m
-5,889,000
Dividend
May 16, 20222 EUR/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Biosynex S.A. specializes in the development, manufacture, and worldwide distribution of rapid diagnostic solutions. Their extensive product line includes a variety of quick diagnostic assays, immunoblots, molecular biology tools, and point-of-care devices. These offerings are vital for screening, diagnosis, and prevention across numerous medical fields, such as bacteriology, parasitology, mycology, virology, biochemistry, oncology, and women's health, alongside specific COVID-19 tests and related instruments. Additionally, Biosynex provides consumer products like self-testing kits, personal health monitoring equipment (including thermometers and blood pressure monitors), and a selection of oral care and medical aid supplies. The company serves a diverse client base, including biological and medical analysis laboratories, hospitals, pharmacies, and large retail outlets like hypermarkets and supermarkets. Founded in 1993, Biosynex S.A. is headquartered in Illkirch-Graffenstaden, France.

Related entities

Subsidiaries
BIOSYNEX SWISS SA

Key people

Larry Abensur
Chairman of the Board, Chief Executive Officer · since 2024
Diane Bessin
Director · since 2024
Elie Fraenckel
Director
Thomas Lamy
Deputy Chief Executive Officer, Director · since 2015
Thierry Paper
Deputy Chief Executive Officer - Research and Business Development, Director · since 2015
IPO date
Mar 21, 2011
Employees
367
Domiciled in
FR
Incorporated in
FR
Headquarters & legal address
22 BOULEVARD SEBASTIEN BRANT
ILLKIRCH-GRAFFENSTADEN 67400
FR

Valuation

Title
EUR in thousands, except ratios and share amounts
FY
2025‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT